Heterologous prime-boost: Breaking the protective immune response bottleneck of COVID-19 vaccine candidates

Approaches and Challenges in SARS-CoV-2 Vaccine Development

(2020) Gabriel Dagotto et al.   Cell Host & Microbe

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes

(2020) Shengli Xia et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

(2020) Feng-Cai Zhu et al.   LANCET

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

(2020) Edward E. Walsh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

(2020) Wen Shi Lee et al.   Nature Microbiology

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

(2020) Maheshi N Ramasamy et al.   LANCET

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

(2020) Peter Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel prime-boost vaccine strategies against HIV-1

(2019) Jean-Louis Excler et al.   Expert Review of Vaccines

Molecular Insight into Dengue Virus Pathogenesis and Its Implications for Disease Control

(2015) Michael S. Diamond et al.   CELL

The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination

(2014) Kristin Hollister et al.   Human Vaccines & Immunotherapeutics

DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus

(2013) Anna Gil et al.   Human Vaccines & Immunotherapeutics

Heterologous HA DNA vaccine prime—inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses

(2008) Shixia Wang et al.   VACCINE